Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 7/20 | 0.71 |
| ▸ | ESR1 | P03372 | 7/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | SHBG | P04278 | 4/20 | 0.67 |
| ▸ | PGR | P06401 | 3/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.67 |
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.67 |
| ▸ | SNCA | P37840 | 3/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | STS | P08842 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15965513 | 0.88 | HSD17B1 (0.56) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL11861252 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL193937 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL8042961 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL10080229 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL23711105 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL13123064 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL224256 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL21631888 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA | |
| SCHEMBL2310466 | 0.87 | HSD17B1 (0.72) | HSD17B1ESR1ESR2HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55049399-A | — | — | None | — | — | JP | disclosed |
| JP-55049399-A | — | — | None | — | — | JP | disclosed |
| JP-55053300-A | — | — | None | — | — | JP | disclosed |
| WO-2008100769-A2 | PROCESS FOR SELECTIVE SULFATION OF AROMATIC HYDROXYL GROUPS | WYETH (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194533-A1 | PROCESS FOR SELECTIVE SULFATION OF AROMATIC HYDROXYL GROUPS | WYETH (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| CN-1867577-A | Estratriene derivatives | CRYPTOPHARMA PTY LTD (AU) | 2006-11-22 | — | — | CN | disclosed |
| EP-1625143-A1 | ESTRATRIENE DERIVATIVES | Cryptopharma Pty Ltd (AU) | 2006-02-15 | — | — | EP | disclosed |
| EP-1424998-A4 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | UNIV PENNSYLVANIA (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004101595-A1 | ESTRATRIENE DERIVATIVES | CRYPTOPHARMA PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
| EP-1424998-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | The Trustees of The University of Pennsylvania (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003015757-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-02-27 | — | — | WO | disclosed |
| JP-S5553300-A | PREPARATION OF 3-HYDROXY-16-BROMOESTRA-1,3,5(10)-TRIEN-17-ONE | MITSUBISHI CHEM IND LTD | 1980-04-18 | — | — | JP | disclosed |
| JP-S5549399-A | PREPARATION OF 3-HYDROXY-16-BROMOESTRA-1,3,5(10)-TRIEN-17- ONE | MITSUBISHI CHEM IND LTD | 1980-04-09 | — | — | JP | disclosed |
| JP-S5549399-A | PREPARATION OF 3-HYDROXY-16-BROMOESTRA-1,3,5(10)-TRIEN-17- ONE | MITSUBISHI CHEM IND LTD | 1980-04-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | HSD17B1 19/4885ESR1 5/4885ESR2 1/4885 |
| US-20080194533-A1 | PROCESS FOR SELECTIVE SULFATION OF AROMATIC HYDROXYL GROUPS | SULT1A1, CYP21A2, SULT2A1 | HSD17B1 24/4885ESR1 9/4885ESR2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.